[Arg1-D-Phe7]-substituted bradykinin analogs inhibit bradykinin- and vasopressin-induced contractions of uterine smooth muscle

SG Farmer, RM Burch, CJ Dehaas, J Togo and LR Steranka

Nova Pharmaceutical Corporation, Baltimore, Maryland.

The purpose of the present study was to examine the tissue selectivity of several [Arg1-D-Phe7]-substituted analogs of bradykinin. Unlike D- Arg-[Hyp3-D-Phe7]-bradykinin (NPC567), which antagonizes bradykinin- induced contractions both in rat isolated uterus and guinea pig ileum, [D-Nal1-Thi5,8-D-Phe7]-bradykinin (NPC573) was active only in uterine smooth muscle. Binding studies revealed that, unlike several [D-Phe7]- substituted analogs, including NPC567, NPC573 competed with radiolabeled bradykinin neither at receptors in uterus nor ileum. Moreover, no [Arg1-D-Phe7]-substituted analog competed with bradykinin binding in guinea pig ileum, suggesting that these agents, which inhibit uterine but not ileal contractions to bradykinin, may not be bradykinin receptor antagonists. NPC573 inhibited [Arg8]-vasopressin- induced contraction of the uterus more potently than it did bradykinin, although NPC573 (and other [Arg1-D-Phe7]-substituted analogs tested) did not inhibit binding of a vasopressin antagonist either in uterus or liver membranes. We therefore suggest that [Arg1-D-Phe7]-substituted analogs of bradykinin inhibit contractions of uterine smooth muscle by a mechanism other than receptor antagonism. In addition, the tissue selectivity of these agents suggests that the mechanisms underlying bradykinin's contractile effect in uterus are different than in intestinal smooth muscle.

Volume 248, Issue 2, pp. 677-681, 02/01/1989
Copyright © 1989 by American Society for Pharmacology and Experimental Therapeutics